Method for establishing the sensitivity of tumours to capecitabin and test kit
AssigneeSanoxsys GmbH
InventorGerhard Schaller
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for establishing the sensitivity of tumors towards capecitabine, if applicable in combination with Docetaxel or Paclitaxel or the humanized antibody Herceptin, or COX-2 inhibitors or angiogenesis inhibitors and test kit. Fields of application of the invention are the pharmaceutical industry and bio-sciences: biology, biochemistry, biotechnology, medicine and medicinal technology.
Claims15
A method for treating a human tumor in a patient, comprising determining the sensitivity of said human tumor to a combination of capecitabine, a COX-2 inhibitor, and an angiogenesis inhibitor, comprised of the following steps:
- (a) obtaining a tumor tissue sample from said human tumor;
- (b) testing said tumor tissue sample to determine a first amount of a group of indicators including thymidine phosphorylase, vascular endothelial growth factor (VEGF), vascular endothelial growth factor-receptor (VEGF-R), and cyclooxygenase 2, wherein the thymidine phosphorylase is detected from a peritumoral fraction of said tumor tissue sample;
- (c) comparing the first amount of each of said group of indicators to a second amount of said group of indicators, wherein said second amount of said group of indicators is obtained from a non-tumor tissue sample;
- and
- (d) determining the sensitivity of said human tumor to capecitabine in combination with the COX-2 inhibitor and the angiogenesis inhibitor, wherein when the first amount is greater than the second amount, the test is indicative of sensitivity, and wherein when the first amount is less than the second amount, the test is indicative of insensitivity;
- and,
- (e) when the test is indicative of sensitivity, administering to said patient harboring the human tumor capecitabine in combination with the COX-2 inhibitor and the angiogenesis inhibitor.
A method for treating a human tumor in a patient, comprising determining the sensitivity of said human tumor to a combination of capecitabine, and a COX-2 inhibitor, comprised of the following steps:
- (a) obtaining a tumor tissue sample from a said human tumor;
- (b) testing said tumor tissue sample to determine a first amount of thymidine phosphorylase and a first amount of cyclooxygenase 2;
- wherein the thymidine phosphorylase is detected from a peritumoral fraction of said tumor tissue sample;
- (c) comparing the first amount of thymidine phosphorylase to a second amount of thymidine phosphorylase and the first amount of cyclooxygenase 2 to a second amount of cyclooxygenase 2, wherein said second amounts are obtained from a non-tumor tissue sample;
- (d) determining the sensitivity of said human tumor to capecitabine in combination with the COX-2 inhibitor, wherein when the first amount of thymidine phosphorylase is greater than the second amount of thymidine phosphorylase and when the first amount of cyclooxygenase 2 is comparable to the second amount of cyclooxygenase 2 or greater, the test is indicative of sensitivity, and wherein when the first amount of thymidine phosphorylase is not greater than the second amount of thymidine phosphorylase or when the first amount of cyclooxygenase 2 is less than the second amount of cyclooxygenase 2, the test is indicative of insensitivity;
- and,
- (e) when the test is indicative of sensitivity, administering to said patient harboring the human tumor capecitabine in combination with the COX-2 inhibitor.
Dependencies are inferred from the claim text.